ARTICLE | Company News
Cancer Targeted Technology, Bayer deal
December 20, 2010 8:00 AM UTC
The companies will collaborate to optimize a PET imaging agent based on Cancer Targeted Technology's enzyme inhibitor scaffold which targets the prostate-specific membrane antigen ( PSMA; FOLH1; GC...